|
1. Biologie
|
|
|
|
|
2.6 Etiologie - Environnement
|
|
|
|
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
|
4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
4.15 Dép., diag. & prono. - imagerie
|
|
|
|
Publication of the Strategic Review of Bioimaging in the UK [BBSRC]
|
|
|
|
|
|
The
UK bioimaging landscape has undergone dramatic changes in recent years.
Taking into account the scientific drivers, technological
breakthroughs, substantial investments made and recent community
mobilisation, as well as the changing European context, it was
considered timely to conduct a strategic review of bioimaging to serve
as an evaluation of BBSRC’s current and future approaches to support for
bioimaging in the UK.
|
|
|
|
|
|
|
5. Traitements
|
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
|
5.5.8 ASCO (poumon)
|
|
|
|
6.10 Politiques
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
6.7.1 IA/bioinformatique
|
|
|
|
|
|